The article describes a dendrimer enhanced taxotere (docetaxel) in vitro experiment. Is there any link between the Starpharma work and this research?
One assumes (as a non biochemist) that the characteristics of the dendrimer would be fairly critical to the way the payload performs. Is this paper just saying that the SPL work is repeatable with other dendrimers or is it the same dendrimer?
The Pipeline, page-18
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $2.457K | 23.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43194 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 115551 | 4 |
View Market Depth
| Last trade - 11.22am 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |